# US 2024/0189272 A1 · Formulations and compositions of docetaxel

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189272 A1
- Document ID: US20240189272A1
- Status: Published application
- Kind: A1
- Application number: 18/387,327
- Filed: 2023-11-06
- Published: 2024-06-13
- Earliest claimed: 2017-05-01
- Applicants: Zhuhai Beihai Biotech Co., Ltd.
- Inventors: Qun Sun
- Web page: https://patentgrep.com/patent/US20240189272A1

## CPC

- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/14: Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)}
- A61K 38/38: Albumins
- A61K 38/385: {Serum albumin}
- A61K 47/18: Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K 47/42: Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34)
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

This document relates to a composition comprising docetaxel, proteins comprising a human serum albumin, and sodium caprylate, wherein the docetaxel and the human serum albumin in the composition have a ratio by weight from about 1:70 to about 1:300, and wherein the composition does not contain sodium N-acetyltryptophanate. This document also relates to a composition consisting essentially of docetaxel, proteins comprising a human serum albumin, and sodium caprylate, wherein the docetaxel and the human serum albumin in the composition have a ratio by weight from about 1:70 to about 1:300, and wherein the composition does not contain sodium N-acetyltryptophanate. This document also relates to a composition comprising docetaxel, proteins comprising a human serum albumin, and sodium N-acetyltryptophanate, wherein the docetaxel and the human serum albumin in the composition have a ratio by weight from about 1:80 to less than 1:150.

## Claims

### Claim 1

A composition comprising docetaxel, proteins comprising a human serum albumin, and sodium caprylate, wherein the docetaxel and the human serum albumin in the composition have a ratio by weight from about 1:70 to about 1:300, and wherein the composition does not contain sodium N-acetyltryptophanate.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the docetaxel and the human serum albumin in the composition are in a ratio by weight from about 1:80 to about 1:150.

### Claim 3 (depends on 1, 2)

The composition of any one of claims 1-2, wherein the human serum albumin is a native human serum albumin.

### Claim 4 (depends on 1, 2, 3)

The composition of any one of claims 1-3, wherein the ratio of the amount of sodium caprylate to the amount of the proteins in the composition is from about 0.140 mmol to about 0.180 mmol of sodium caprylate per one gram of the proteins.

### Claim 5 (depends on 1, 2, 3, 4)

The composition of any one of claims 1-4, wherein the composition is a solid formulation.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The composition of any one of claims 1-5, wherein the composition is an aqueous formulation.

### Claim 7 (depends on 1, 2, 3, 4, 5)

The composition of any one of claims 1-5, wherein the aqueous formulation is substantially free of solvent other than water.

### Claim 8 (depends on 6, 7)

The composition of any one of claims 6-7, wherein the aqueous formulation is a clear aqueous solution.

### Claim 9 (depends on 6, 7, 8)

The composition of any one of claims 6-8, wherein the aqueous formulation is a clear aqueous solution for at least 1 hours, at least 2 hours, at least 3 hours, at least 4 hours, at least 5 hours, at least 6 hours, at least 8 hours, or at least 24 hours.

### Claim 10

A composition comprising docetaxel, proteins comprising a human serum albumin, and N-acetyltryptophanate, wherein the docetaxel and the human serum albumin in the composition have a ratio by weight from about 1:80 to less than 1:150.

### Claim 11 (depends on 10)

The composition of claim 10, wherein the docetaxel and the human serum albumin in the composition are in a ratio by weight from about 1:90 to about 1:140.

### Claim 12 (depends on 10, 11)

The composition of any one of claims 10-11, wherein the human serum albumin is a native human serum albumin.

### Claim 13 (depends on 10, 11, 12)

The composition of any one of claims 10-12, wherein the composition comprises from about 0.064 mmol to about 0.096 mmol sodium N-acetyltryptophanate and from about 0.064 mmol to about 0.096 mmol sodium caprylate per gram of the proteins in the composition.

### Claim 14 (depends on 10, 11, 12, 13)

The composition of any one of claims 10-13, wherein the composition is a solid formulation.

### Claim 15 (depends on 10, 11, 12, 13)

The composition of any one of claims 10-13, wherein the composition is an aqueous formulation.

### Claim 16 (depends on 15)

The composition of claim 15, wherein the aqueous formulation is substantially free of solvent other than water.

### Claim 17 (depends on 15, 16)

The composition of any one of claims 15-16, wherein the aqueous formulation is a clear aqueous solution.

### Claim 18 (depends on 15, 16, 17)

The composition of any one of claims 15-17, wherein the aqueous formulation is a clear aqueous solution for at least 1 hours, at least 2 hours, at least 3 hours, at least 4 hours, at least 5 hours, at least 6 hours, at least 8 hours, or at least 24 hours.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

A pharmaceutical composition comprising the composition of any one of claims 1-18, and a pharmaceutically acceptable carrier.

### Claim 20 (depends on 19)

A method of treating a cancer, the method comprising the step of administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition of claim 19.

### Claim 21 (depends on 20)

The method of claim 20, wherein the cancer is selected from the group consisting of breast cancer, non-small cell lung cancer, prostate cancer, gastric cancer, head and neck cancer, ovarian cancer, pancreatic cancer, and Kaposi's sarcoma.
